{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:12:06Z","timestamp":1788495126277,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13014-018-1035-9","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T23:32:05Z","timestamp":1525217525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0687","authenticated-orcid":false,"given":"Pierfrancesco","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Arcadipane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Andrikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Carlo","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mistrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"258","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;258:71\u201396.","journal-title":"CA Cancer J Clin"},{"key":"1035_CR2","first-page":"1943","volume":"36","author":"P Franco","year":"2016","unstructured":"Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Rondi N, et al. Early-stage node negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36:1943\u20138.","journal-title":"Anticancer Res"},{"key":"1035_CR3","first-page":"2027","volume":"36","author":"P Franco","year":"2016","unstructured":"Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Rondi N, et al. Locally advanced (T3-T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36:2027\u201332.","journal-title":"Anticancer Res"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCCR Anal cancer Trial Working Party","year":"1996","unstructured":"UKCCCR Anal cancer Trial Working Party. UK Co-ordination Committee on Cancer Research: Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049\u201354.","journal-title":"Lancet"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and gastrointestinal cooperative group. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mytomicin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339.","journal-title":"J Clin Oncol"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914\u201321.","journal-title":"JAMA"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACTII): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516\u201324.","journal-title":"Lancet Oncol"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/DCR.0b013e31819eb7f0","volume":"52","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients for the National Cancer Data Base. Dis Colon rectum. 2009;52:624\u201331.","journal-title":"Dis Colon rectum"},{"key":"1035_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cncr.20364","volume":"101","author":"LG Johnson","year":"2004","unstructured":"Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology and end results experience. Cancer. 2004;101:281\u20138.","journal-title":"Cancer"},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.27825","volume":"119","author":"R Glynne-Jones","year":"2013","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, et al. Prognostic factors for recurrence and survival in anal cancer. Cancer. 2013;119:748\u201355.","journal-title":"Cancer"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1002\/cncr.25188","volume":"116","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer. The intergroup trial (RTOG 98-11). Cancer. 2010;116:4007\u201313.","journal-title":"Cancer"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1515\/raon-2015-0015","volume":"50","author":"I Oblak","year":"2016","unstructured":"Oblak I, Cesnjevar M, Anzic M, Hadzic JB, Ermenc AS, Anderluh F, et al. The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of the anal canal and anal margin. Radiol Oncol. 2016;50:113\u201320.","journal-title":"Radiol Oncol"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/0284186X.2011.653438","volume":"51","author":"CM Hoff","year":"2012","unstructured":"Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol. 2012;51:419\u201332.","journal-title":"Acta Oncol"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/DCR.0b013e3181d964c1","volume":"53","author":"GB Roldan","year":"2010","unstructured":"Roldan GB, Chan AK, Buckner M, Magliocco AM, Doll CM. The prognostic value of hemoglobin in patients with anal cancer treated with chemoradiotherapy. Dis Colon rectum. 2010;53:1127\u201334.","journal-title":"Dis Colon rectum"},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","volume":"18","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a posthoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017;18:347\u201356.","journal-title":"Lancet Oncol."},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mytomycin C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/07357907.2015.1028586","volume":"33","author":"P Franco","year":"2015","unstructured":"Franco P, Mistrangelo M, Arcadipane F, Munoz F, Sciacero P, Spadi R, et al. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Investig. 2015;33:259\u201366.","journal-title":"Cancer Investig"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"2015832","DOI":"10.1259\/bjr.20150832","volume":"89","author":"P Franco","year":"2016","unstructured":"Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Munoz F, et al. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Br J Radiol. 2016;89:2015832.","journal-title":"Br J Radiol"},{"key":"1035_CR20","doi-asserted-by":"publisher","unstructured":"Arcadipane F, Franco P, Ceccarelli M, Furfaro G, Rondi N, Trino E, et al. Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. Asia Pac J Clin Oncol Aug 30. doi: \n                    https:\/\/doi.org\/10.1111\/ajco.12768\n                    \n                  . [Epub ahead of print] (2017).","DOI":"10.1111\/ajco.12768"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00066-006-1543-7","volume":"182","author":"P Vaupel","year":"2006","unstructured":"Vaupel P, Mayer A, Hockel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol. 2006;182:63\u201371.","journal-title":"Strahlenther Onkol"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","volume":"77","author":"M Nordsmark","year":"2005","unstructured":"Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18\u201324.","journal-title":"Radiother Oncol"},{"key":"1035_CR23","first-page":"302","volume":"3","author":"R Bush","year":"1978","unstructured":"Bush R, Jenkin RD, Alt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978;3:302\u20136.","journal-title":"Br J Cancer Suppl"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0360-3016(97)00329-5","volume":"39","author":"EC Constantinou","year":"1997","unstructured":"Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997;39:651\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1035_CR25","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer- and chemotherapy-induced anemia. At \n                    www.nccn.org\n                    \n                   as accessed on 18th Dec 2017."},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/codi.13342","volume":"18","author":"ZA Kapacee","year":"2016","unstructured":"Kapacee ZA, Susnerwala M, Wise M, Biswas A, Danwata F, Scott N. Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors. Color Dis. 2016;18:1080\u20136.","journal-title":"Color Dis"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737140.2017.1288104","volume":"17","author":"P Franco","year":"2017","unstructured":"Franco P, Arcadipane F, Ragona R, Mistrangelo M, Cassoni P, Racca P, et al. Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Rev Anticancer Ther. 2017;17:335\u201345.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12094-016-1504-2","volume":"19","author":"P Franco","year":"2017","unstructured":"Franco P, Ragona R, Arcadipane F, Mistrangelo M, Cassoni P, Rondi N, et al. Dosimentric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol. 2017;19:67\u201375.","journal-title":"Clin Transl Oncol"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12032-016-0789-x","volume":"33","author":"P Franco","year":"2016","unstructured":"Franco P, Arcadipane F, Ragona R, et al. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. Med Oncol. 2016;33:72.","journal-title":"Med Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-018-1035-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T19:16:16Z","timestamp":1556738176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-1035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/s13014-018-1035-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval for the present study was given by the Review Board of the Department of Oncology of the University of Turin. Written informed consent was acquired from all patients with respect to RT treatment and clinical data management for research purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}